1 / 44

Clinical Management of Lymphoma

Clinical Management of Lymphoma. 新光醫院 血液腫瘤科 溫 武 慶. Malignant Lymphoma. Neoplastic lymphoid cells Arrested at different stages of normal differentiation Tumor formation in the lymph nodes (usually) or extranodal areas. 90.9.28. 90.11.28. 91.03.13. Classification of Lymphoma.

hannah-long
Download Presentation

Clinical Management of Lymphoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Management of Lymphoma 新光醫院 血液腫瘤科 溫 武 慶

  2. Malignant Lymphoma • Neoplastic lymphoid cells • Arrested at different stages of normal differentiation • Tumor formation in the lymph nodes (usually) or extranodal areas

  3. 90.9.28 90.11.28 91.03.13

  4. Classification of Lymphoma • Hodgkin lymphoma (HL) • Classic (CHL) • LR (lymphocyte-rich) • LD (lymphocyte-depleted) • MC (mixed cellularity) 17% • NS (nodular sclerosis) 80% • NLPHL (nodular lymphocyte predominant) 3-8% • Non-Hodgkin lymphoma (NHL) • B-cell, T-cell • High, intermediate, low grade (REAL/WHO classification)

  5. Differences in HL and NHL • HL • NHL RS or L & H cells Lymphoma cells diffuse nodular

  6. Differences in HL and NHL

  7. Lymphoma Work-up • Diagnosis and Classification • Stage • Other prognostic factors • Age • LDH • Beta-2 microglobulin • IPI (international prognostic index)

  8. Staging Work-up • CBC, platelet • LDH, biochemistry • CXR, chest/abdomen/pelvic CT • PET scan • Bone marrow examination

  9. Lymphoma Stage • 1974 Ann Arbor, 1988 Cotswolds • I 1 single LN region or lymphoid structure • II > 2 LN regions on the same side of diaphragm (No. of LNs indicated by a subscript e.g. II2) • III LN regions or lymphoid structures on both sides of the diaphragm • III1 splenic hilar, celiac, or portal LNs • III2 PALN, iliac, mesenteric LNs • IV > 2 extranodal sites

  10. Lymphoma Stage • A: no symptoms • B: fever, night sweating, BW loss (any one) • X: bulky disease • Mediastinal mass > 1/3 of maximum transverse chest diameter • LN > 10cm • E: single extranodal site (contiguous or proximal to a known LN stie)

  11. A = without symptoms, B = with symptoms including unexplained weight loss 10% in 6 months), unexplained fever, and drenching night sweats

  12. Lymph Node Region

  13. Gastric Lymphoma Stage

  14. SL/CLL Stage

  15. Principles of NHL Treatment • Low risk • Stage I, II C/T + R/T • Stage III, IV observation, C/T • Intermediate~ high grade • Stage I, II C/T + R/T • Stage III, IV C/T

  16. NHL Treatment- DLBCL(diffuse large B-cell lymphoma)

  17. NHL Treatment- DLBCL(diffuse large B-cell lymphoma)

  18. NHL Treatment- DLBCLIPI • 5ys: score 0-1 73%; 2 51%; 3 43%; 4-5 26%

  19. NHL Treatment-FL

  20. NHL Treatment-FL(follicular lymphoma)

  21. NHL Treatment-FL Median survival 8-10y

  22. NHL Treatment-Margional Zone Lymphoma

  23. NHL Treatment-Margional Zone Lymphoma Median survival 10y

  24. NHL Treatment-MCL(Mantle Cell Lymphoma)

  25. NHL Treatment-MCL Median survival 3-5y

  26. NHL Treatment-SL/CLL(small lymphocytic lymphoma)

  27. NHL Treatment-SL/CLL Median survival: 10 y

  28. NHL Treatment-Burkitt Lymphoma

  29. NHL Treatment-PTL

  30. NHL Treatment-PTL

  31. NHL Treatment-PTL 5 year survival 25%

  32. HL TreatmetPrognostic factors

  33. HL treatment- Classic HL • Stage IA, IIA, nonbulky, cure rate: >90% • C/T (ABVD) + IFRT (category 1) • C/T only (ABVD x 6) (category 2B) • Stage I, II, bulky, cure rate >80% • Stage III, IV, cure rate 60-70% • ABVD x 4 -> restage -> 2-4 cycles -> observe or IFRT • Stanford V x 3 -> restage + R/T • Escalated BEACOPP (if IPS > 4)

  34. Classic HL Treatmet-C/T

  35. NLPHL Treatmet • I-IIA: IFRT or regional R/T • I-IIB: C/T + IFRT • III-IVA • C/T + R/T • local R/T • observation (category 2B) • III-IVB: C/T + R/T

  36. NLPHL Treatmet-C/T • 10 year survival 80%

  37. HL Treatmet-R/T

  38. PET in lymphoma

  39. International Harmonization Project in Lymphoma • PET scanning before treatment is recommended only for those lymphomas that are routinely avid for labeled glucose (eg, DLBCL, Hodgkin lymphoma)]. There is not sufficient evidence in support of the use of PET scanning for lymphomas other than DLBCL and Hodgkin Lymphoma. • Use of PET for treatment monitoring during a course of therapy should only be done as part of a clinical trial or as part of a prospective registry. • PET scanning after completion of therapy should be performed at least three weeks and preferably at six to eight weeks after chemotherapy or chemo-immunotherapy and 8 to 12 weeks after radiation or chemoradiotherapy. • Mediastinal blood pool activity is recommended as the reference background activity to define PET positivity for a residual mass ≥2 cm in greatest transverse diameter, regardless of location. • A smaller residual mass or a normal sized lymph node (ie, ≤1 x 1 cm in diameter) should be considered positive if its activity is above that of the surrounding background. • There is no role for the use of PET to follow patients in remission. • JCO 2007 25;571-8

More Related